Exames Laboratoriais - Resultados

Text Material Preview

<p>Test Name Result Unit Bio. Ref. Range Method</p><p>COMPLETE BLOOD COUNT (CBC) , WHOLE BLOOD EDTA</p><p>HAEMOGLOBIN 8.4 g/dL 12-15 Spectrophotometer</p><p>PCV 28.50 % 36-46 Electronic pulse &</p><p>Calculation</p><p>RBC COUNT 4.79 Million/cu.mm 3.8-4.8 Electrical Impedence</p><p>MCV 59.4 fL 83-101 Calculated</p><p>MCH 17.5 pg 27-32 Calculated</p><p>MCHC 29.4 g/dL 31.5-34.5 Calculated</p><p>R.D.W 25.2 % 11.6-14 Calculated</p><p>TOTAL LEUCOCYTE COUNT (TLC) 6,850 cells/cu.mm 4000-10000 Electrical Impedance</p><p>DIFFERENTIAL LEUCOCYTIC COUNT (DLC)</p><p>NEUTROPHILS 63 % 40-80 Electrical Impedance</p><p>LYMPHOCYTES 31 % 20-40 Electrical Impedance</p><p>EOSINOPHILS 0.8 % 1-6 Electrical Impedance</p><p>MONOCYTES 4.5 % 2-10 Electrical Impedance</p><p>BASOPHILS 0.7 % <1-2 Electrical Impedance</p><p>CORRECTED TLC 6,850 Cells/cu.mm Calculated</p><p>ABSOLUTE LEUCOCYTE COUNT</p><p>NEUTROPHILS 4315.5 Cells/cu.mm 2000-7000 Calculated</p><p>LYMPHOCYTES 2123.5 Cells/cu.mm 1000-3000 Calculated</p><p>EOSINOPHILS 54.8 Cells/cu.mm 20-500 Calculated</p><p>MONOCYTES 308.25 Cells/cu.mm 200-1000 Calculated</p><p>BASOPHILS 47.95 Cells/cu.mm 0-100 Calculated</p><p>Neutrophil lymphocyte ratio (NLR) 2.03 0.78- 3.53 Calculated</p><p>PLATELET COUNT 219000 cells/cu.mm 150000-410000 Electrical impedence</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 12:40PM</p><p>Reported : 14/Mar/2024 01:34PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF HAEMATOLOGY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:HA06644079</p><p>Page 1 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>ERYTHROCYTE SEDIMENTATION</p><p>RATE (ESR) , WHOLE BLOOD EDTA</p><p>20 mm at the</p><p>end of 1 hour</p><p>0-20 Modified Westergren</p><p>Result is rechecked. Kindly correlate clinically</p><p>Comment:</p><p>1. ESR is an acute phase reactant which indicates presence and severity of an inflammatory process. ESR is not diagnostic of any specific disease. ESR is a</p><p>screening test with low sensitivity. CRP has better sensitivity than ESR.</p><p>2. ESR Test is used to monitor the course or response to treatment of certain diseases.</p><p>3. ESR is an indirect measure of the extent of inflammation (infections, autoimmune disorders, certain anemias & malignancies).</p><p>4. There are many dieases such as typhoid in which ESR is not increased.</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 12:40PM</p><p>Reported : 14/Mar/2024 03:34PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF HAEMATOLOGY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:HA06644079</p><p>Page 2 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>GLUCOSE, FASTING , NAF PLASMA 98 mg/dL 70-100 GOD - POD</p><p>Comment:</p><p>As per American Diabetes Guidelines, 2023</p><p>Fasting Glucose Values in mg/dL Interpretation</p><p>70-100 mg/dL Normal</p><p>100-125 mg/dL Prediabetes</p><p>≥126 mg/dL Diabetes</p><p><70 mg/dL Hypoglycemia</p><p>Note:</p><p>1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2</p><p>occasions.</p><p>2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>HBA1C (GLYCATED HEMOGLOBIN) , WHOLE BLOOD EDTA</p><p>HBA1C, GLYCATED HEMOGLOBIN 5.8 % HPLC</p><p>ESTIMATED AVERAGE GLUCOSE</p><p>(eAG)</p><p>120 mg/dL Calculated</p><p>Comment:</p><p>Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:</p><p>REFERENCE GROUP HBA1C %</p><p>NON DIABETIC <5.7</p><p>PREDIABETES 5.7 – 6.4</p><p>DIABETES ≥ 6.5</p><p>DIABETICS</p><p>EXCELLENT CONTROL 6 – 7</p><p>FAIR TO GOOD CONTROL 7 – 8</p><p>UNSATISFACTORY CONTROL 8 – 10</p><p>POOR CONTROL >10</p><p>Note: Dietary preparation or fasting is not required.</p><p>1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 12:40PM</p><p>Reported : 14/Mar/2024 05:44PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF BIOCHEMISTRY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:BI18791183</p><p>Page 3 of 14</p><p>Control by American Diabetes Association guidelines 2023.</p><p>2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.</p><p>3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation</p><p>is advised in interpretation of low Values.</p><p>4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age.</p><p>HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.</p><p>5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control</p><p>A: HbF >25%</p><p>B: Homozygous Hemoglobinopathy.</p><p>(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 12:40PM</p><p>Reported : 14/Mar/2024 05:44PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF BIOCHEMISTRY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:BI18791183</p><p>Page 4 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>LIPID PROFILE , SERUM</p><p>TOTAL CHOLESTEROL 112 mg/dL <200 CHE/CHO/POD</p><p>TRIGLYCERIDES 75 mg/dL <150 Enzymatic</p><p>HDL CHOLESTEROL 43 mg/dL >40 CHE/CHO/POD</p><p>NON-HDL CHOLESTEROL 69 mg/dL <130 Calculated</p><p>LDL CHOLESTEROL 54 mg/dL <100 Calculated</p><p>VLDL CHOLESTEROL 15 mg/dL <30 Calculated</p><p>CHOL / HDL RATIO 2.60 0-4.97 Calculated</p><p>ATHEROGENIC INDEX (AIP) < 0.01 <0.11 Calculated</p><p>Comment:</p><p>Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.</p><p>Desirable</p><p>Borderline</p><p>High</p><p>High</p><p>Very</p><p>High</p><p>TOTAL CHOLESTEROL < 200 200 - 239 ≥ 240</p><p>TRIGLYCERIDES <150 150 - 199</p><p>200 -</p><p>499</p><p>≥ 500</p><p>LDL</p><p>Optimal < 100; Near Optimal 100-</p><p>129</p><p>130 - 159</p><p>160 -</p><p>189</p><p>≥ 190</p><p>HDL ≥ 60</p><p>NON-HDL CHOLESTEROL</p><p>Optimal <130; Above Optimal</p><p>130-159</p><p>160-189 190-219 >220</p><p>ATHEROGENIC INDEX(AIP) <0.11 0.12 – 0.20 >0.21</p><p>Note:</p><p>1) Measurements in the same patient on different days can show physiological and analytical variations.</p><p>2) NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.</p><p>3) Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine</p><p>eligibility of drug therapy.</p><p>4) Low HDL levels are associated with coronary heart disease due to insufficient HDL being available to participate in reverse</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 12:58PM</p><p>Reported : 14/Mar/2024 04:09PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF BIOCHEMISTRY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:BI18791181</p><p>Page 5 of 14</p><p>cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.</p><p>5) As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children</p><p>above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high</p><p>total</p><p>cholesterol is recommended.</p><p>6) VLDL, LDL Cholesterol Non-HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when</p><p>Triglycerides are below 400 mg/dl. When</p><p>Triglycerides are more than 400 mg/dl LDL cholesterol is a direct measurement.</p><p>7) Triglycerides and HDL-cholesterol in Atherogenic index (AIP) reflect the balance between the atherogenic and protective</p><p>lipoproteins. Clinical studies have shown that AIP (log (TG/HDL) & values used are in mmol/L) predicts cardiovascular risk and</p><p>a useful measure of response to treatment (pharmacological intervention).</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 12:58PM</p><p>Reported : 14/Mar/2024 04:09PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF BIOCHEMISTRY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:BI18791181</p><p>Page 6 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>LIVER FUNCTION TEST (LFT) , SERUM</p><p>BILIRUBIN, TOTAL 0.30 mg/dL 0.20-1.20 DIAZO METHOD</p><p>BILIRUBIN CONJUGATED (DIRECT) 0.10 mg/dL 0.0-0.3 Calculated</p><p>BILIRUBIN (INDIRECT) 0.20 mg/dL 0.0-1.1 Dual Wavelength</p><p>ALANINE AMINOTRANSFERASE</p><p>(ALT/SGPT)</p><p>16 U/L 9-52 UV with P-5-P</p><p>ASPARTATE AMINOTRANSFERASE</p><p>(AST/SGOT)</p><p>21.0 U/L 14-36 UV with P-5-P</p><p>ALKALINE PHOSPHATASE 94.00 U/L 38-126 p-nitrophenyl</p><p>phosphate</p><p>PROTEIN, TOTAL 7.30 g/dL 6.3-8.2 Biuret</p><p>ALBUMIN 4.20 g/dL 3.5 - 5 Bromocresol Green</p><p>GLOBULIN 3.10 g/dL 2.0-3.5 Calculated</p><p>A/G RATIO 1.35 0.9-2.0 Calculated</p><p>Comment:</p><p>LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis</p><p>(ALP, GGT), protein synthesis (Albumin)</p><p>Common patterns seen:</p><p>1. Hepatocellular Injury:</p><p>• AST – Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.</p><p>• ALT – Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing</p><p>BMI .• Disproportionate increase in AST, ALT compared with ALP. • Bilirubin may be elevated.</p><p>• AST: ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen</p><p>to be increased in NAFLD, Wilsons’s diseases, Cirrhosis, but the increase is usually not >2.</p><p>2. Cholestatic Pattern:</p><p>• ALP – Disproportionate increase in ALP compared with AST, ALT.</p><p>• Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.</p><p>• To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.</p><p>3. Synthetic function impairment: • Albumin- Liver disease reduces albumin levels.• Correlation with PT (Prothrombin Time) helps.</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 12:58PM</p><p>Reported : 14/Mar/2024 04:09PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF BIOCHEMISTRY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:BI18791181</p><p>Page 7 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM</p><p>CREATININE 0.60 mg/dL 0.5-1.04 Creatinine</p><p>amidohydrolase</p><p>UREA 6.42 mg/dL 15-36 Urease</p><p>BLOOD UREA NITROGEN 3.0 mg/dL 8.0 - 23.0 Calculated</p><p>URIC ACID 3.60 mg/dL 2.5-6.2 Uricase</p><p>CALCIUM 8.20 mg/dL 8.4 - 10.2 Arsenazo-III</p><p>PHOSPHORUS, INORGANIC 3.40 mg/dL 2.5-4.5 PMA Phenol</p><p>SODIUM 143 mmol/L 135-145 Direct ISE</p><p>POTASSIUM 4.0 mmol/L 3.5-5.1 Direct ISE</p><p>CHLORIDE 95 mmol/L 98 - 107 Direct ISE</p><p>PROTEIN, TOTAL 7.30 g/dL 6.3-8.2 Biuret</p><p>ALBUMIN 4.20 g/dL 3.5 - 5 Bromocresol Green</p><p>GLOBULIN 3.10 g/dL 2.0-3.5 Calculated</p><p>A/G RATIO 1.35 0.9-2.0 Calculated</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 12:58PM</p><p>Reported : 14/Mar/2024 04:09PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF BIOCHEMISTRY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:BI18791181</p><p>Page 8 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>CALCIUM , SERUM 8.20 mg/dL 8.4 - 10.2 Arsenazo-III</p><p>Comments:-</p><p>Serum calcium measurements are done to monitor and diagnose disorders of skeletal system, parathyroid gland, kidney, muscular</p><p>disorders, and abnormal vitamin D and protein levels.</p><p>Decreased in: Parathyroid mediated, Vitamin D Deficiency, Liver disease and malnutrition</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>C-REACTIVE PROTEIN CRP</p><p>(QUANTITATIVE) , SERUM</p><p>3 mg/L <10.0 IMMUNOENZYMATIC</p><p>Comment:</p><p>C-reactive protein (CRP) is one of the most sensitive acute-phase reactants for inflammation. Measuring changes in the</p><p>concentration of CRP provides useful diagnostic information about the level of acuity and severity of a disease. Unlike ESR, CRP</p><p>levels are not influenced by hematologic conditions such as anemia, polycythemia etc.</p><p>Increased levels are consistent with an acute inflammatory process. After onset of an acute phase response, the serum CRP</p><p>concentration rises rapidly (within 6-12 hours and peaks at 24-48 hours) and extensively.Concentrations above 100 mg/L are</p><p>associated with severe stimuli such as major trauma and severe infection (sepsis).</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 12:58PM</p><p>Reported : 14/Mar/2024 04:09PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF BIOCHEMISTRY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:BI18791181</p><p>Page 9 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>IRON , SERUM 23.0 µg/dL 60-180 TPTZ</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 03:00PM</p><p>Reported : 14/Mar/2024 03:48PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF BIOCHEMISTRY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:BI18796769</p><p>Page 10 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>VITAMIN B12 , SERUM 126 pg/mL 107.2-653.3 CLIA</p><p>Comment:</p><p>Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of proprioception,</p><p>poor coordination, and affective behavioral changes.</p><p>The most common cause of deficiency is malabsorption either due to atrophy of gastric mucosa or diseases of terminal ileum.</p><p>Patients taking vitamin B12 supplementation may have misleading results.</p><p>A normal serum concentration of B12 does not rule out tissue deficiency of vitamin B12 .</p><p>The most sensitive test for B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and</p><p>homocysteine should be considered, even if serum B12 concentrations are normal.</p><p>Increased levels can be seen in Chronic renal failure, Congestive heart failure, Leukemias, Polycythemia vera, Liver disease etc.</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 03:08PM</p><p>Reported : 14/Mar/2024 04:24PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF IMMUNOLOGY</p><p>APOLLO FULL BODY CHECKUP</p><p>- ADVANCE</p><p>SIN No:IM07153109</p><p>Page 11 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>COMPLETE URINE EXAMINATION (CUE) , URINE</p><p>PHYSICAL EXAMINATION</p><p>COLOUR PALE YELLOW PALE YELLOW Visual</p><p>TRANSPARENCY CLEAR CLEAR Visual</p><p>pH 6.5 5-7.5 Bromothymol Blue</p><p>SP. GRAVITY 1.010 1.002-1.030 Dipstick</p><p>BIOCHEMICAL EXAMINATION</p><p>URINE PROTEIN NEGATIVE NEGATIVE PROTEIN ERROR OF</p><p>INDICATOR</p><p>GLUCOSE NEGATIVE NEGATIVE GOD-POD</p><p>URINE BILIRUBIN NEGATIVE NEGATIVE AZO COUPLING</p><p>URINE KETONES (RANDOM) NEGATIVE NEGATIVE NITROPRUSSIDE</p><p>UROBILINOGEN NORMAL NORMAL EHRLICH</p><p>BLOOD NEGATIVE NEGATIVE Dipstick</p><p>NITRITE NEGATIVE NEGATIVE Dipstick</p><p>LEUCOCYTE ESTERASE NEGATIVE NEGATIVE PYRROLE</p><p>HYDROLYSIS</p><p>CENTRIFUGED SEDIMENT WET MOUNT AND MICROSCOPY</p><p>PUS CELLS 3-4 /hpf 0-5 Microscopy</p><p>EPITHELIAL CELLS 5-6 /hpf <10 MICROSCOPY</p><p>RBC NIL /hpf 0-2 MICROSCOPY</p><p>CASTS NIL 0-2 Hyaline Cast MICROSCOPY</p><p>CRYSTALS ABSENT ABSENT MICROSCOPY</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 01:57PM</p><p>Reported : 14/Mar/2024 03:37PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF CLINICAL PATHOLOGY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:C02676761</p><p>Page 12 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>HBsAg , SERUM 0.14 S/C UNITS ECLIA</p><p>Comment:</p><p>VALUE IN S/C UNITS INTERPRETATION</p><p><0.90 NEGATIVE</p><p>0.90 - 1.00 INDETERMINATE</p><p>> 1.00 POSITIVE</p><p>Interpretation:</p><p>• This is a screening assay which detects the first serological marker of Hepatitis B as early as 4-16 weeks after exposure.</p><p>• It persists during acute illness and usually disappears 12-20 weeks after onset of symptoms. Persistence of HBsAg for more than</p><p>6 months indicates development of carrier state or chronic liver disease</p><p>• A negative test result does not exclude with certainty a possible exposure to or an infection with the hepatitis B virus.</p><p>• It is recommended that a positive result of HBsAg must be be confirmed using a different enzyme immunoassay kit or by using a</p><p>confirmatory assay based on neutralisation with human anti hepatitis B surface antibody and/or HBV PCR</p><p>• Based upon clinical history it may become necessary to test for presence of other markers of hepatitis B virus infection.</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 03:07PM</p><p>Reported : 14/Mar/2024 04:35PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF SEROLOGY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:SE02069229</p><p>Page 13 of 14</p><p>Test Name Result Unit Bio. Ref. Range Method</p><p>ANTI HCV , SERUM 0.03 S/C UNITS ECLIA</p><p>Comment:</p><p>VALUE IN S/C UNITS RESULTS</p><p><0.99 NON-REACTIVE</p><p>0.99 - 1.00 INDETERMINATE</p><p>> 1.00 REACTIVE</p><p>Interpretation:</p><p>• This is a Screening assay.HCV Antibodies are usually not detectable during the first 2 months following infection, and they are</p><p>usually detectable by the late convalescent stage (>6 months of onset) of infection.</p><p>• A positive result indicates the presence of Hepatitis C virus (HCV) – specific IgG antibodies due to past (resolved) or chronic</p><p>Hepatitis C. CDC recommendation on anti-HCV testing includes the use of method specific optimal signal-to-cut-off ratio in</p><p>interpretation & reporting results. For s/co ratio - between 1 to 6- further supplemental tests are suggested for confirmation, while</p><p>s/co ratio > or = 6 associated with 95% or more high probability of being true positive.</p><p>• Suggested supplemental test for confirmation are direct detection of HCV RNA by the reverse transcriptase-PCR (RT-PCR)</p><p>• An indeterminate result indicates that HCV-specific IgG antibodies may or may not be present.Indeterminate results should be</p><p>interpreted along with patient's risk factors for HCV infection and clinical findings. Individuals at risk for HCV infection with</p><p>indeterminate results should be retested with an HCV antibody confirmatory test in 1 to 2 months to determine the definitive HCV</p><p>antibody status.</p><p>• A non-reactive result does not exclude the possibility of exposure to or infection with HCV.Patients with auto-immune liver</p><p>diseases, renal disorders may show falsely reactive results.</p><p>*** End Of Report ***</p><p>Result/s to Follow:</p><p>CA 72.4, ALLERGY, CANDIDA ALBICANS, CA 125, 25-HYDROXY VITAMIN D (D2+D3), THYROID PROFILE TOTAL (T3, T4, TSH)</p><p>Patient Name : Ms.JYOTI KRISHNA NAYAK</p><p>Age/Gender : 26 Y 10 M 11 D /F</p><p>UHID/MR No : ODB1.0000589458</p><p>Visit ID : DMNEOPV30070</p><p>Ref Doctor : Dr.SELF</p><p>IP/OP NO :</p><p>Collected : 14/Mar/2024 09:18AM</p><p>Received : 14/Mar/2024 03:07PM</p><p>Reported : 14/Mar/2024 04:35PM</p><p>Status : Final Report</p><p>Client Name : PUP 24X7_CREDIT</p><p>Patient location : Munnekola,Bangalore</p><p>DEPARTMENT OF SEROLOGY</p><p>APOLLO FULL BODY CHECKUP - ADVANCE</p><p>SIN No:SE02069229</p><p>Page 14 of 14</p>